# Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

> **NCT03672851** · PHASE1 · TERMINATED · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 2 (actual)

## Conditions studied

- Acute Leukemia
- Acute Leukemia in Relapse
- Acute Myeloid Leukemia
- Relapsed or Refractory Acute Leukemia

## Interventions

- **DRUG:** anti-CD123 CAR-T treatment

## Key facts

- **NCT ID:** NCT03672851
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-17
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** adverse effect
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672851, "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03672851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*